Today, the US NIH awarded Pataigin a research grant to further development of Pataigin’s Rigel antimicrobial susceptibility test.
“We thank the NIH for supporting this research,” said Pataigin CEO Erik Nilsson. “Rigel promises to reduce medical costs while saving lives now lost to infectious disease.”
The grant, entitled Isotopic Labeling Rapid Antimicrobial Susceptibility Testing, furthers development of a rapid and sensitive Rigel AST test using lipid microbiology technology. Rigel can determine appropriate antibiotic therapy in six hours, compared to days for conventional tests.
“Rigel is based on my lab’s longstanding research into lipid microbiology,” said Prof. Robert Ernst, the Dr. Paul and Mrs. Jean Corcoran Professor and Chair, Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore. “In this research, we extend lipid microbiology beyond microbial ID to antimicrobial susceptibility testing.” Prof. Ernst is a collaborator on the grant.
Bacteremia and sepsis remain major health problems with high mortality. Progression is often rapid, so that a single hour saved in diagnosis time can significantly reduce septicemia death rates. Faster tests are therefore needed to save lives. By significantly accelerating test results, Rigel assay offers the potential of improved clinical outcomes at lower cost to hospitals.